Seems almost negligent that they don't mention 1 vs 2 studies and we need to read between the lines here. If they are pursuing a single study wouldn't that be worth clearing up once and for all and putting an end to the speculation. Its called an informed market. Maybe they did actually say they are going for one trial in the following sentence but jeez just spell it out for investors please!
"The Company now intends to meet with its key regulatory and clinical advisors in the coming weeks
to better understand the Type C meeting response from FDA, and in particular, to determine the
best direction and design for a Phase III study of Presendin™ in IIH."
Seems almost negligent that they don't mention 1 vs 2 studies...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
